BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizos CV, Filippatos TD, Elisaf MS. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2018;14:117-25. [PMID: 29241374 DOI: 10.1080/17425255.2018.1418325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Gallwitz B, Schmieder R. Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin. Diabetologie und Stoffwechsel 2020;15:317-326. [DOI: 10.1055/a-1197-6223] [Reference Citation Analysis]
2 Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf 2018;17:837-48. [PMID: 30068236 DOI: 10.1080/14740338.2018.1497159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Aroor AR, Manrique-Acevedo C, DeMarco VG. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol 2018;17:59. [PMID: 29669555 DOI: 10.1186/s12933-018-0704-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
4 Scheen A. Perspectives dans le traitement pharmacologique du diabète de type 2 pour les 10 prochaines années. Médecine des Maladies Métaboliques 2018;12:174-181. [DOI: 10.1016/s1957-2557(18)30043-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]